VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYNB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYNBKyntra Bio, Inc.
$2.04$15M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
KYNB logo

Kyntra Bio, Inc.

KYNB
NASDAQ · Oncology Biotech
$2.04
At close - Nov 17, 4:00 PM EST - USD
Market Cap$8M
P/E0.2x
52W High$10.47
Volume238.96K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Kyntra Bio Revenue Volatility Masks Persistent Operating Cash Burn Risk

KYNB's reported revenue has swung erratically, from $46.3M in 2024Q3 to roughly $1.8M in 2026Q3, making a durable growth trajectory difficult to establish, while operating income remained deeply negative at -$12.9M in the latest quarter.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

KYNB price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-99% Peers

P/E is 99% below peer median

03

Market leadership

RS 6 · Lag

Laggard (Underperforming 94% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
KYNB-77.73%
S&P 500 (^GSPC)+7.21%
1-Year Return
KYNB-76.55%
S&P 500 (^GSPC)+10.03%
3-Year Return
KYNB-85.69%
S&P 500 (^GSPC)+22.62%
5-Year Return
KYNB-99.34%
S&P 500 (^GSPC)+35.85%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
0.2x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
0.2x
0.2x
100th· High
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$6M-78.3% YoY
Net income FY25
$183M+485.6% YoY
Free cash flow FY25
-$5M+96.5% YoY
Operating margin FY25
-712.7%-204.9 pts YoY
ROIC (FY25)-
Avg ROIC 5Y-318.6%
ROE (FY25)4099.5%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
$0.04+101.1%
vs -$3.55
$2M+1.9%
vs $2M
Q3 2026
Aug 13, 2026
$2.96+193.1%
vs -$3.18
$2M-171.8%
vs $2M
Q2 2026
May 11, 2026
-$3.74-11.3%
vs -$3.36
$4M+137.9%
vs $2M
Q2 2026
Mar 16, 2026
-$3.51+9.8%
vs -$3.89
$1M-22.2%
vs $2M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·2d ago
Kyntra Bio (KYNB) Reports Q3 Loss, Misses Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of a loss of $3.66. This compares to a loss of $1.61 per share a year ago.

GlobeNewsWire·2d ago
Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden (HTB) planned in 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise Decision to discontinue development of FG-3246 and FG-3180 following insufficient efficacy at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer (mCRPC), resulting in a reduction of over $20 million in operating expenses in 2027 and 2028 Cash, cash equivalents, investments, and accounts receivable of $44.1 million as of September 30, 2026, with a cash runway now into 2028 Kyntra Bio to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the third quarter 2026 and provided an update on the company's recent developments. “Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wettig, Chief Executive Officer of Kyntra Bio.

GlobeNewsWire·5d ago
Kyntra Bio to Report Third Quarter 2026 Financial Results

SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Defense World·Nov 11, 2026
Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Average Price Target of $36.80 According to Analysts

Kyntra Bio Inc (NASDAQ: KYNB - Get Free Report) has earned an average rating of "Hold" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts

Filtered for Kyntra Bio, Inc.More Headlines
04

Compare before deciding

Benchmark KYNB against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Kyntra Bio, Inc. (KYNB)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
KYNB logoKYNBKyntra Bio, Inc.Current
$2.04$8.26M0.24-78.26%657.67%4099.49%—
AKBA logoAKBAAkebia Therapeutics, Inc.
$0.40$107.41M-2.4947.46%-22.6%-169.15%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.36$5.01B-47.55114.51%-9.17%——
RARE logoRAREUltragenyx Pharmaceutical Inc.
$16.70$1.64B-3.2520.13%-71.78%——
INSM logoINSMInsmed Incorporated
$121.86$26.41B-44.0266.73%-39.85%-82.75%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$42.99$6.06B-8.41-45.65%-160.64%-172.62%—

Compare KYNB vs Peers

Kyntra Bio, Inc. (KYNB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AKBA

Most directly comparable listed peer for KYNB.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare KYNB against a more recognizable public peer.

Peer Set

Compare Top 5

vs AKBA, PTCT, RARE, INSM

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

KYNB SEC Filings & Documents

Kyntra Bio, Inc. (KYNB) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 6, 2026·SEC

Material company update

Oct 1, 2026·SEC

Material company update

Aug 31, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 16, 2026·SEC

FY 2025

Mar 17, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

May 12, 2026·SEC

FY 2025

Nov 10, 2025·SEC

Get notified when KYNB posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

KYNB Frequently Asked Questions

Kyntra Bio, Inc. (KYNB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Kyntra Bio, Inc.'s revenue?

Kyntra Bio, Inc. (KYNB) reported $5.3M in revenue over the trailing twelve months. Revenue was $6.4M in fiscal year 2025. That is 90% less than the $65.9M of fiscal year 2012.

How fast is Kyntra Bio, Inc. growing?

Kyntra Bio, Inc. (KYNB) grew revenue by 104.5% over the trailing twelve months, compared with the twelve months before.

Is KYNB profitable?

Yes. Kyntra Bio, Inc. (KYNB) earned $34.9M in net income over the trailing twelve months (a 657.7% net margin).

Dividend & Returns
What is KYNB's return on equity?

Kyntra Bio, Inc. (KYNB) had a return on equity (ROE) of 4099.5% in fiscal year 2025. That is well above the market's typical 10-15%.

What is Kyntra Bio, Inc.'s free cash flow?

Kyntra Bio, Inc. (KYNB) had negative free cash flow of $48.5M over the trailing twelve months.

What if you invested $1,000 in KYNB back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →